# US 2020/0138763 A1 · Methods for increasing oral osteogenesis using lipoxin a4 (lxa4) and its analogs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0138763 A1
- Document ID: US20200138763A1
- Status: Published application
- Kind: A1
- Application number: 16/594,602
- Filed: 2019-10-07
- Published: 2020-05-07
- Earliest claimed: 2013-02-21
- Assignees: Forsyth Dental Infirmary for Children
- Applicants: Forsyth Dental Infirmary for Children
- Inventors: Thomas E. Van Dyke; Hatice Hasturk; Alpdogan Kantarci
- Web page: https://patentgrep.com/patent/US20200138763A1

## CPC

- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0063: {Periodont}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides methods for increasing oral osteogenesis using LXA4 and its analogs. Methods are also provided for treating or preventing oral disorders that would benefit from increased oral osteogenesis using LXA4 and its analogs.

## Claims

### Claim 1

A method of treating or preventing an oral disorder by increasing oral osteogenesis in a subject in need thereof comprising administering a therapeutically effective amount of lipoxin A4 (LXA4) or an analog thereof to the oral cavity of the subject to thereby treat or prevent the oral disorder by increasing oral osteogenesis.

### Claim 2 (depends on 1)

The method of claim 1, wherein the oral disorder is selected from the group consisting of periodontitis, alveolar bone loss, gingivitis, osteoporosis, osteopenia, oral bone resection, oral bone fracture, arthritis, osteoarthritis, osteotomy bone loss, osteolytic lesions, and childhood idiopathic bone loss.

### Claim 3 (depends on 1)

The method of claim 1, wherein the LXA4 or analog thereof is formulated in a pharmaceutically acceptable carrier.

### Claim 4 (depends on 3)

The method of claim 3, wherein the pharmaceutically acceptable carrier is selected from the group consisting of mouth rinses, tooth pastes, dentifrice, buccal patch, dental fibre, dental tape, chewing gum, food additives, lozenges, tablet, chewable capsule, intraoral delivery devices and encapsulated in resporbable carrier nanoparticles of biologic or synthetic origin.

### Claim 5 (depends on 1)

The method of claim 1, wherein the effective amount of the agent is an amount that increases oral osteogenesis and/or reduces oral bone reabsorption.

### Claim 6 (depends on 1)

The method of claim 1, further comprising administering at least one additional agent that treats the oral disorder that would benefit from increased oral osteogenesis.

### Claim 7 (depends on 6)

The method of claim 6, wherein the additional agent is selected from the group consisting of anti-inflammatory agents and antimicrobial agents.

### Claim 8 (depends on 1)

The method of claim 1, wherein the LXA4 analog is 9,12 benzo-LXA4.

### Claim 9 (depends on 1)

The method of claim 1, wherein the administration is topical.

### Claim 10

A method of treating periodontal disease in a subject in need thereof comprising:
a) performing periodontal flap surgery upon at least one periodontal lesion of the subject; and
b) administering a therapeutically effective amount of LXA4 or an analog thereof to the surgical wound at the time of surgery;
to thereby treat the periodontal disease in the subject.

### Claim 11 (depends on 10)

The method of claim 10, wherein the periodontal disease is selected from the group consisting of periodontitis, gingivitis, chronic periodontitis, aggressive periodontitis, necrotizing periodontal disease, periodontium abcesses, and post-operative gingival infections.

### Claim 12 (depends on 10)

The method of claim 10, wherein the LXA4 or analog thereof is formulated in a pharmaceutically acceptable carrier.

### Claim 13 (depends on 12)

The method of claim 12, wherein the pharmaceutically acceptable carrier is selected from the group consisting of mouth rinses, tooth pastes, dentifrice, buccal patch, dental fibre, dental tape, chewing gum, food additives, lozenges, tablet, chewable capsule, intraoral delivery devices and encapsulated in resporbable carrier nanoparticles of biologic or synthetic origin.

### Claim 14 (depends on 10)

The method of claim 10, wherein the effective amount of the LXA4 or analog thereof is an amount that increases oral osteogenesis and/or reduces oral bone reabsorption.

### Claim 15 (depends on 10)

The method of claim 10, further comprising administering at least one additional agent that treats the periodontal disease.

### Claim 16 (depends on 15)

The method of claim 15, wherein the additional agent is selected from the group consisting of anti-inflammatory agents and antimicrobial agents.

### Claim 17 (depends on 10)

The method of claim 10, wherein the LXA4 analog is 9,12 benzo-LXA4.

### Claim 18 (depends on 10)

The method of claim 10, wherein the administration is topical.

### Claim 19 (depends on 10)

The method of claim 10, further comprising the step of administering a therapeutically effective amount of LXA4 or an analog thereof to the at least one periodontal lesion at least one time after periodontal flap surgery completion.

### Claim 20 (depends on 19)

The method of claim 19, wherein the LXA4 analog is 9,12 benzo-LXA4.

### Claim 21 (depends on 10)

The method of claim 10, further comprising administering at least one additional agent that treats the periodontal disease at least one time after periodontal flap surgery completion.

### Claim 22 (depends on 21)

The method of claim 21, wherein the additional agent is selected from the group consisting of anti-inflammatory agents and antimicrobial agents.

### Claim 23 (depends on 10)

The method of claim 10, wherein the administration is topical.
